Phase 2 Studies of Novel JAK1 Inhibitor for HS Show Promise Phase 2 Studies of Novel JAK1 Inhibitor for HS Show Promise

Results of the two phase 2 studies"establish proof of concept" for the JAK1 inhibitor for the treatment of moderate to severe hidradenitis suppurativa, the investigators concluded.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Source Type: news